Pennsylvania news: Personalized treatment for deadly blood and bone marrow cancer
WFMZ-TV in Allentown, Pennsylvania recently highlighted the University of Cincinnati's John Byrd and the Beat AML study testing personalized treatment for patients with acute myelogenous leukemia.
“Although it has one name there are probably 15, 20 different types of AML. Before, when people were diagnosed with AML, they would come in and everybody would be treated the same way,” said Byrd, MD, a University of Cincinnati Cancer Center researcher, chair of the Department of Internal Medicine at the UC College of Medicine and the chief medical officer of the Beat AML study.
Using genetic sequencing, researchers are identifying what drives each patient's disease and personalizing treatments accordingly.
“Once a medicine gets approved in one indication, it can potentially be applied to a lot of other types of cancers that have that same mutation, but might be in a different part of the body,” Byrd said.
The Beat AML trial is unique because it a master trial studying multiple drugs at the same time.
Featured photo at top of Erin Hertlein, PhD, left, and John Byrd, MD, working in the lab. Photo/UC Foundation.
Related Stories
Is a colonoscopy painful?
May 13, 2026
The University of Cincinnati's Susan Kais, MD, assistant professor of clinical medicine in the Division of Gastroenterology and Hepatology in the College of Medicine and UC Health gastroenterologist, recently appeared on the ARC Cincinnati morning program on Local 12/WKRC-TV to answer common questions from viewers about colonoscopies and to dispel myths.
Telescope captures information about lonely Jupiter-like gas giant
May 13, 2026
Science outlets highlight a University of Cincinnati student's collaborative discoveries about an exoplanet 901 light years away.
UC achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy
May 13, 2026
Researchers at the University of Cincinnati Gardner Neuroscience Institute’s Brain Tumor Center have been confirmed as the first in the world to achieve complete remission of a rare pituitary cancer using a novel immunotherapy treatment. The findings were published in Surgical Neurology International and recently featured in The Cancer Letter.